Cardiomyopathies Clinical Trial
Official title:
HIS-Purkinje Conduction System Pacing Optimized Trial of Cardiac Resynchronization Therapy
This is a randomized, prospective, single-blinded trial to determine the overall rate of successful His-Purkinje conduction system pacing Optimized Trial of Cardiac Resynchronization Therapy (HOT-CRT) versus biventricular pacing using coronary sinus lead (BVP) to compare acute and mid-term outcomes. Acute outcomes include change in QRS duration pre-and post-pacing (degree of QRS narrowing) and incidence of major periprocedural complications (pericardial tamponade, need for lead revision, etc.). Mid-term outcomes include echocardiographic response at 6 months along with a composite clinical outcome of heart failure hospitalization, ventricular arrhythmias, crossover, and all-cause mortality.
This is a single-blinded study of 100 patients randomized to a strategy of His-Purkinje conduction system pacing Optimized Trial of Cardiac Resynchronization Therapy (HOT-CRT) versus biventricular pacing using coronary sinus (CS) lead (BVP). Both treatment options use standard-of-care, FDA-approved devices. The distinction is only in the allocation toward HOT-CRT and BVP. Treating physicians will be aware of assignment in order to facilitate routine device follow-up. Echocardiographic and electrocardiographic evaluation will also be performed in a blinded manner. Cross-over is permitted between treatment group allocation if: CS lead cannot be placed due to difficult cannulation of the CS, limited branches at the posterolateral or lateral wall, or phrenic nerve capture. These subjects may then cross-over to HOT-CRT. HOT-CRT subjects may cross-over if His or left bundle pacing lead cannot be positioned with adequate stability and reasonable pacing output, or if optimal QRS narrowing cannot be achieved. Implant procedure will be per routine percutaneous access, as is standard for pacemaker and Implantable Cardioverter Defibrillators (ICDs). . All subjects will receive an FDA-approved cardiac resynchronization therapy pacemaker or defibrillator device, as per standard of care outlined for the subject. Follow-up will be performed at 2 weeks post-implant for incision check and device interrogation as is standard of care. In addition, routine device and clinical follow-up will be scheduled at 3 and 6 months. Electrocardiography (ECG) will be performed pre-implant, prior to hospital discharge, at 3 months, and 6 months. Echocardiography will be performed pre-implant and 6 months to evaluate for change in Left Ventricular Ejection Fraction (LVEF), chamber dimensions, volumes, and change in Left Ventricular (LV) end systolic volume index as is standard of care in the treatment of patients with advanced heart failure. New York Heart Association (NYHA) functional class and quality of life (utilizing the Kansas City Cardiomyopathy Questionnaire (KCCQ) and EQ 5D) will be assessed pre-implant and at 6 months. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05428787 -
Resynchronization in Patients With HF in AF Trial Undergoing Pace & AVNA Strategy With LBBAP Compared With BiV Pacing
|
N/A | |
Not yet recruiting |
NCT05567445 -
Outcome of Cardiomyopathic Adults Admission in ICU.
|
||
Completed |
NCT02555527 -
Contrast Echocardiography Cost Effectiveness for Left Ventricular Thrombus Assessment
|
N/A | |
Completed |
NCT00371891 -
Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
|
Phase 4 | |
Recruiting |
NCT05552521 -
Diastolic Dysfunction in Septic Shock and Cardiomyopathy Genetic Variants
|
||
Recruiting |
NCT04166331 -
Adjunctive DobutAmine in sePtic Cardiomyopathy With Tissue Hypoperfusion
|
Phase 3 | |
Terminated |
NCT06331507 -
Refinement and Assessment of New MRI Technologies for Cardiovascular Exams Using the Phillips CMR Patch
|
N/A | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Recruiting |
NCT04695119 -
Sepsis in the ICU-II
|
||
Completed |
NCT03228966 -
Ped HIV - Echo Study: Kenya
|
||
Not yet recruiting |
NCT06348732 -
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings
|
||
Recruiting |
NCT05556369 -
Genetic Characterization of Cardiomyopathies (POLICARDIOMIO2021)
|
||
Recruiting |
NCT04520646 -
A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy
|
N/A | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT04323852 -
Can Vitamin D Reduce Heart Muscle Damage After Bypass Surgery?
|
Phase 4 | |
Completed |
NCT03527381 -
Nitric Oxide in Cardiopulmonary Bypass for Renal Protection in Cardiac Surgery
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02462213 -
Prospective Identification of Cardiac Amyloidosis by Cardiac Magnetic Resonance Imaging
|
N/A | |
Active, not recruiting |
NCT00418041 -
Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)
|
N/A | |
Not yet recruiting |
NCT06091475 -
Therapy to Maintain Remission in Dilated Cardiomyopathy
|
N/A | |
Recruiting |
NCT03317964 -
Genetic Basis of Pacing-induced Cardiomyopathy
|